Julian Maressa, DO
Adult Medicine · Berlin, NJNPI 1275643116
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 61 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by Novo Nordisk at 29.5% of the total. Reporting peaked in 2019 at $474 and has fallen 93.2% since, to $32 in 2025.
Across 61 payments — averaging $13.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$241
- Alkermes, Inc.$178
- Eisai Inc.$42
- GSK$42
- Otsuka America Pharmaceutical, Inc.$42
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$30
- plus $242 from 13 others
What the payments were for
- Food & beverage$816100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 20 | $241 |
| Alkermes, Inc. | 12 | $178 |
| Eisai Inc. | 3 | $42 |
| GSK | 3 | $42 |
| Otsuka America Pharmaceutical, Inc. | 3 | $42 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $30 |
| Merck | 2 | $28 |
| Nalpropion Pharmaceuticals LLC | 2 | $27 |
| Kaleo, Inc. | 2 | $27 |
| Novartis | 2 | $25 |
| Sanofi Pasteur Inc. | 2 | $23 |
| Metuchen Pharmaceuticals | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Jazz Pharmaceuticals Inc. | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $15 |
| Antares Pharma, Inc. | 1 | $14 |
| Lilly USA, LLC | 1 | $13 |
| Currax Pharmaceuticals LLC | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
How this compares
$816 in reported general payments places this provider in the 75th percentile of 48 adult medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxycontinOxycodone Hcl | 40 | $40,169 |
| RexultiBrexpiprazole | 13 | $36,185 |
| MounjaroTirzepatide | 22 | $27,679 |
| EliquisApixaban | 15 | $20,697 |
| EntrestoSacubitril/Valsartan | 13 | $19,300 |
| FarxigaDapagliflozin Propanediol | 18 | $16,774 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $12,538 |
| TrintellixVortioxetine Hydrobromide | 12 | $9,564 |
| Metaxalone | 12 | $9,121 |
| JardianceEmpagliflozin | 11 | $8,709 |
| Oxycodone Hcl | 182 | $5,492 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 20 | $4,693 |
| Alprazolam | 310 | $4,404 |
| Butorphanol Tartrate | 12 | $3,089 |
| Lidocaine | 15 | $2,695 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $42 | $36,18513 claims |
| Lilly USA, LLCMounjaro | $13 | $27,67922 claims |
| NovartisEntresto | $25 | $19,30013 claims |
| GSKTrelegy Ellipta | $42 | $12,53819 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 48 adult medicine providers in New Jersey.
Other adult medicine in Berlin
- Michael HassmanBerlin$14K
- Michael ReutterBerlin$7K
- Boris EpsteinE Brunswick$7K
- Kathleen CarpioNeptune$7K
- Shamim SaeedShrewsbury$6K
- Dimpal RanaClifton$4K
- Leslie SimonsonWest Orange$3K
- Andrea RuizHackensack$2K
- Mary BelloMahwah$2K
- Jolly KuruvillaWest Orange$840
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.